Lung Foundation NZ acknowledges decision to fund durvalumab
Pharmac’s decision to fund immunotherapy treatment durvalumab (imfinzi) for stage 3 lung cancer is a small step forward.
Lung Foundation New Zealand (LFNZ) acknowledges the leaders and clinical advisors at Pharmac and the key people at AstraZeneca for getting durvalumab (imfinzi) across the line.
This funding decision also highlights extreme inequities with access to treatments continue to persist for NZ’s Biggest Cancer Killer.
Click to view LFNZ’s statement –
2022 March – Lung Foundation NZ response to Pharmac’s decision to fund Durvalumab (Imfinzi) for Stage III lung cancer